Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GPSM2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GPSM2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GPSM2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GPSM2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GPSM2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GPSM2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051651111 | Esophagus | ESCC | maintenance of location in cell | 126/8552 | 214/18723 | 6.57e-05 | 5.00e-04 | 126 |
GO:009016914 | Esophagus | ESCC | regulation of spindle assembly | 21/8552 | 25/18723 | 9.12e-05 | 6.54e-04 | 21 |
GO:190437719 | Esophagus | ESCC | positive regulation of protein localization to cell periphery | 47/8552 | 69/18723 | 1.37e-04 | 9.27e-04 | 47 |
GO:0000132 | Esophagus | ESCC | establishment of mitotic spindle orientation | 23/8552 | 30/18723 | 5.47e-04 | 3.00e-03 | 23 |
GO:00400011 | Esophagus | ESCC | establishment of mitotic spindle localization | 26/8552 | 35/18723 | 5.57e-04 | 3.04e-03 | 26 |
GO:00512941 | Esophagus | ESCC | establishment of spindle orientation | 27/8552 | 37/18723 | 7.00e-04 | 3.66e-03 | 27 |
GO:00328864 | Esophagus | ESCC | regulation of microtubule-based process | 134/8552 | 240/18723 | 9.44e-04 | 4.80e-03 | 134 |
GO:00516533 | Esophagus | ESCC | spindle localization | 37/8552 | 56/18723 | 1.65e-03 | 7.65e-03 | 37 |
GO:19021174 | Esophagus | ESCC | positive regulation of organelle assembly | 42/8552 | 67/18723 | 3.72e-03 | 1.52e-02 | 42 |
GO:0051293 | Esophagus | ESCC | establishment of spindle localization | 33/8552 | 51/18723 | 4.77e-03 | 1.85e-02 | 33 |
GO:190382922 | Liver | HCC | positive regulation of cellular protein localization | 199/7958 | 276/18723 | 1.15e-23 | 2.62e-21 | 199 |
GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
GO:005149522 | Liver | HCC | positive regulation of cytoskeleton organization | 138/7958 | 226/18723 | 1.26e-08 | 3.12e-07 | 138 |
GO:000705111 | Liver | HCC | spindle organization | 116/7958 | 184/18723 | 1.40e-08 | 3.40e-07 | 116 |
GO:000716322 | Liver | HCC | establishment or maintenance of cell polarity | 133/7958 | 218/18723 | 2.48e-08 | 5.73e-07 | 133 |
GO:190437521 | Liver | HCC | regulation of protein localization to cell periphery | 83/7958 | 125/18723 | 5.60e-08 | 1.19e-06 | 83 |
GO:000705211 | Liver | HCC | mitotic spindle organization | 80/7958 | 120/18723 | 7.43e-08 | 1.50e-06 | 80 |
GO:005123521 | Liver | HCC | maintenance of location | 185/7958 | 327/18723 | 1.70e-07 | 3.12e-06 | 185 |
GO:190285011 | Liver | HCC | microtubule cytoskeleton organization involved in mitosis | 93/7958 | 147/18723 | 2.91e-07 | 5.09e-06 | 93 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GPSM2 | SNV | Missense_Mutation | | c.1114C>G | p.Gln372Glu | p.Q372E | P81274 | protein_coding | tolerated(0.15) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GPSM2 | SNV | Missense_Mutation | | c.1463G>C | p.Gly488Ala | p.G488A | P81274 | protein_coding | tolerated(0.14) | benign(0.011) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
GPSM2 | SNV | Missense_Mutation | | c.1629C>A | p.Asn543Lys | p.N543K | P81274 | protein_coding | tolerated(0.49) | benign(0.015) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GPSM2 | SNV | Missense_Mutation | rs867670266 | c.815N>T | p.Ala272Val | p.A272V | P81274 | protein_coding | tolerated(0.06) | probably_damaging(0.948) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GPSM2 | SNV | Missense_Mutation | | c.1672N>A | p.Arg558Ser | p.R558S | P81274 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GPSM2 | SNV | Missense_Mutation | | c.1258N>A | p.Glu420Lys | p.E420K | P81274 | protein_coding | tolerated(0.1) | benign(0.08) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GPSM2 | SNV | Missense_Mutation | | c.970N>A | p.Ala324Thr | p.A324T | P81274 | protein_coding | deleterious(0.02) | benign(0.241) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
GPSM2 | SNV | Missense_Mutation | | c.1778C>A | p.Ala593Asp | p.A593D | P81274 | protein_coding | deleterious(0.03) | benign(0.078) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
GPSM2 | SNV | Missense_Mutation | novel | c.1525T>C | p.Cys509Arg | p.C509R | P81274 | protein_coding | deleterious(0) | possibly_damaging(0.677) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GPSM2 | SNV | Missense_Mutation | novel | c.1673G>C | p.Arg558Pro | p.R558P | P81274 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |